| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 85,080 | 63,812 |
| Net increase (decrease) in cash | 9,919 | -12,337 |
| Cash and cash equivalents at beginning of period | 315,353 | - |
| Cash and cash equivalents at end of period | 325,272 | - |
Axsome Therapeutics, Inc. (AXSM)
Axsome Therapeutics, Inc. (AXSM)